XENOTHERA closes a new capital increase above 2 million euros

17 June 2016

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more than 2 million euros.
Created by a medical team specialized in organ transplantation and a veterinary world-renowned in animal cloning, XENOTHERA is a young company specialized in immunology and genetic engineering.

Press Release Fundraising XENOTHERA June 2016 final